Ann: Positive Safety Data from Third Cohort of PI Clinical Trial, page-22

@ionade I am not sure your view on courage or brains is respectful. Everybody has a risk tolerance and junior pharma companies are high risk. Most at our stage will fail.

Published success rates of academic drugdiscovery and development are 75% at phase I, 50% at phase II, 59% at phaseIII, and 88% at the new drug application/biologics license application (NDA/BLA)phase. Multiply all of those together and the probability of success sits at 19%. Therefore we are likely to fail. The reward has to reflect the high probability that this will be a dud.

What do you see that tilts these odds in our favor and warrants taking the risk? BTW I am invested and have my own views on why the risk is worth taking and lower than these whole of industry success rates.

If we get to 4000mg/kg with tolerable toxicity our chances of success go up to 26% without another variable changing. Still pretty risky.